Dupilumab is indicated for severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/08/2021|
|Rapid review completed||23/09/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.